Patient-reported Outcome Measurement Group, Department of Public Health, University of Oxford, Old Road Campus, Oxford, OX3 7LF, UK.
Br J Dermatol. 2013 Jun;168(6):1176-86. doi: 10.1111/bjd.12310.
The collection of patient-reported outcome measures (PROMs) within the national PROMs programme for elective procedures is now established mandatory practice in the NHS with high response rates and completion.
This review examines the evidence of PROMs for people with skin cancer.
Comprehensive searches were conducted using several sources and databases, using a detailed search strategy developed by the University of Oxford's PROM Group. Articles were assessed for eligibility. Data were extracted per PROM for each measurement property and appraised using an appraisal framework.
A total of 3517 articles were identified in the searches, and 28 were included in the final review after assessment by two independent reviewers. Two generic instruments (SF-36 and Sickness Impact Profile) and nine condition-specific PROMs were identified.
Overall, there is a limited volume of published evidence for the application of generic PROMs for people with skin cancer. Evaluation of the EQ-5D may be particularly important given its widespread use in many other healthcare contexts in the U.K. The Skin Cancer Index could be considered for piloting in the NHS. For patients with nonmelanoma skin cancers, the Skindex measures may also be considered. The SCQOLIT has some evidence of applicability across both skin cancer types but more evaluations are needed. The FACT-M does have more promising characteristics for patients with malignant melanomas although no evidence of testing in the U.K. was found. The forthcoming EORTC-M may prove a useful measure given the expertise and track record of this European collaboration in cancer and quality of life.
在英国国家患者报告结局测量(PROMs)计划中收集择期手术的 PROMs 现已成为强制性实践,具有较高的响应率和完成率。
本综述检查了皮肤癌患者 PROMs 的证据。
使用几种来源和数据库进行了全面搜索,使用由牛津大学 PROM 小组开发的详细搜索策略。评估文章的合格性。针对每个测量属性,按 PROM 提取数据,并使用评估框架进行评估。
共在搜索中确定了 3517 篇文章,经过两位独立审稿人的评估,最终有 28 篇文章被纳入最终综述。确定了两种通用工具(SF-36 和 Sickness Impact Profile)和 9 种特定于疾病的 PROMs。
总体而言,关于通用 PROMs 在皮肤癌患者中的应用,仅有有限数量的已发表证据。鉴于 EQ-5D 在英国许多其他医疗保健环境中的广泛应用,对其进行评估可能尤为重要。皮肤癌指数可以考虑在国民保健制度中进行试点。对于非黑色素瘤皮肤癌患者,Skindex 措施也可以考虑。SCQOLIT 在两种皮肤癌类型中都具有一定的适用性证据,但需要进行更多评估。FACT-M 对恶性黑色素瘤患者具有更有希望的特征,但在英国没有发现测试证据。即将推出的 EORTC-M 可能是一种有用的测量方法,因为该欧洲合作组织在癌症和生活质量方面具有专业知识和良好记录。